Opperman L A, Galanis V, Williams A R, Adab K
Department of Biomedical Sciences and Center for Craniofacial Research and Diagnosis, Baylor College of Dentistry, Texas A & M University System Health Science Center, Dallas 75266-0677, USA.
Orthod Craniofac Res. 2002 Feb;5(1):5-16. doi: 10.1034/j.1600-0544.2002.01179.x.
Appropriate biochemical regulation of intramembranous bone growth from sutures is necessary to achieve correct craniofacial morphology. Failure to form sutures (agenesis) or to maintain sutures in their unossified state (craniosynostosis) can result in severe facial dysmorphology. Several factors such as Twist, Msx2, fibroblast growth factors (Fgfs), bone morphogenetic proteins (Bmps) and transforming growth factors-beta (Tgf-betas) regulate suture patency, likely by interacting with one another. Tgf-beta2 and Tgf-beta3 use the same cell surface receptors, yet have opposite effects on suture patency, cellular proliferation and apoptosis within the suture. One possible mechanism by which Tgf-beta3 rescues sutures from obliteration is by regulating the ability of suture cells to respond to Tgf-beta2. As Tgf-beta3 does not regulate protein levels of Tgf-beta2 in sutures, Tgf-beta3 could regulate tissue responsiveness to Tgf-beta2 by regulating Tgf-beta2 access to receptors. Tgf-beta3 is a more potent competitor than Tgf-beta2 for cell surface receptors, so it is proposed that Tgf-beta3 binds to and down-regulates Tgf-beta receptor type I (Tbetar-I) expression by suture cells. This down-regulation would limit the ability of cells to respond to all Tgf-betas, including Tgf-beta2. To test this hypothesis, an in vitro culture model was used in which fetal rat sutures either remain patent or are induced to fuse when cultured in the presence or absence of dura mater, respectively. Tgf-beta3 was added to cultured calvaria and changes in the number of receptor positive cells within the suture were established. Data were compared with that seen in control sutures and in normal sutures in vivo. It was found that the numbers of cells expressing Tbetar-I within the suture matrix increased over time in sutures remaining patent. Osteoblastic cells lining the bone fronts on either side of sutures were Tbetar-I positive during early morphogenesis, but these numbers declined as sutures fused, both in vivo and in vitro. Addition of Tgf-beta3 to calvaria in culture decreased the number of Tbetar-I expressing cells in both fusing and non-fusing sutures, with dramatic decreases in the numbers of osteoblasts expressing Tbetar-I.
为实现正确的颅面形态,来自缝线的膜内骨生长需要适当的生化调节。无法形成缝线(发育不全)或无法使缝线维持未骨化状态(颅缝早闭)会导致严重的面部畸形。诸如Twist、Msx2、成纤维细胞生长因子(Fgfs)、骨形态发生蛋白(Bmps)和转化生长因子-β(Tgf-βs)等多种因素调节缝线的通畅性,可能是通过彼此相互作用来实现的。Tgf-β2和Tgf-β3使用相同的细胞表面受体,但对缝线通畅性、细胞增殖以及缝线内的细胞凋亡具有相反的作用。Tgf-β3使缝线免于闭塞的一种可能机制是调节缝线细胞对Tgf-β2作出反应的能力。由于Tgf-β3不调节缝线中Tgf-β2的蛋白质水平,Tgf-β3可能通过调节Tgf-β2与受体的结合来调节组织对Tgf-β2的反应性。Tgf-β3比Tgf-β2对细胞表面受体更具竞争力,因此有人提出Tgf-β3与缝线细胞表面的I型Tgf-β受体(Tbetar-I)结合并下调其表达。这种下调会限制细胞对所有Tgf-βs(包括Tgf-β2)作出反应的能力。为了验证这一假设,使用了一种体外培养模型,在该模型中,分别在有或没有硬脑膜的情况下培养胎鼠缝线时,缝线要么保持通畅,要么被诱导融合。将Tgf-β3添加到培养的颅骨中,并确定缝线内受体阳性细胞数量的变化。将数据与对照缝线和体内正常缝线中的数据进行比较。发现在保持通畅的缝线中,缝线基质内表达Tbetar-I的细胞数量随时间增加。在早期形态发生过程中,缝线两侧骨前沿的成骨细胞为Tbetar-I阳性,但随着缝线融合,无论是在体内还是体外,这些细胞数量都会减少。在培养的颅骨中添加Tgf-β3会减少融合和未融合缝线中表达Tbetar-I的细胞数量,其中表达Tbetar-I的成骨细胞数量显著减少。